Immunogenicity of BNT162b2 vaccine after two and three doses in health personnel and institutionalized elderly people not infected with SARS-CoV-2

  1. M. Rodríguez-Prieto 1
  2. F. Modino-García 1
  3. C. de la Arada-Benavides 1
  4. R. de la Puente 2
  5. A. Carvajal 2
  6. I. Rodríguez-Cabañeros 3
  7. C. de Prado-Santos 3
  8. B. de Mota-Luna 3
  9. T. Fernández-Villa 2
  10. J.P. Fernández-Váquez 4
  11. V. Martín 2
  1. 1 Centro de Salud La Palomera, León, Spain
  2. 2 Universidad de León
    info

    Universidad de León

    León, España

    ROR https://ror.org/02tzt0b78

  3. 3 Centro de Salud La Bañeza, León, Spain
  4. 4 Gerencia de atención primaria, León, Spain
Mostrar afiliaciones +
Revista:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Año de publicación: 2024

Número: 1

Páginas: 2-2

Tipo: Artículo

DOI: 10.1016/J.SEMERG.2023.102092 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Semergen: revista española de medicina de familia

Objetivos de desarrollo sostenible

Resumen

Objective The aim of our research was to compare the evolution of the immune response induced by the BNT162b2 vaccine after the administration of two and three doses in healthcare personnel and in institutionalized elderly people (>65 years of age) without previous SARS-CoV-2 infection. Material and methods A prospective observational study was carried out on a convenience sample made up of health workers and institutionalized elderly people, measuring antibodies against S and N proteins of SARS-CoV-2 two and six months after receiving the second vaccine dose, as well as two months after receiving the third dose. Results A significant reduction of the anti-S humoral immune response was reported six months after the second dose of vaccine in both health workers and residents. The administration of a third dose of vaccine induced a significant increase in this antibody response in both investigated groups reaching a similar proportion of responders two months after this third dose. Conclusions Humoral immunity induced by two doses of the BNT162b2 vaccine in persons without prior SARS-CoV-2 infection wanes over time. The administration of a third dose significantly increases anti-S antibodies being highly recommended, especially in people over 65 years of age.

Referencias bibliográficas

  • S.J. Thomas, E.D. Moreira Jr., N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months N Engl J Med, 385 (2021), pp. 1761-1773 View article CrossRefGoogle Scholar
  • J. Keehner, L.E. Horton, N.J. Binkin, L.C. Laurent, SEARCH Alliance, D. Pride, et al. Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce N Engl J Med, 385 (2021), pp. 1330-1332 View article CrossRefView in ScopusGoogle Scholar
  • J.A. Juno, A.K. Wheatley Boosting immunity to COVID-19 vaccines Nat Med, 27 (2021), pp. 1874-1875 View PDF This article is free to access. CrossRefView in ScopusGoogle Scholar
  • E. Blanco-Tarrío, G. Blanco Sánchez Primary care, residential homes for the elderly, and COVID-19 Semergen, 46 (2020), pp. 26-34 View PDFView articleView in ScopusGoogle Scholar
  • V.J. Hall, S. Foulkes, A. Charlett, A. Atti, E.J.M. Monk, R. Simmons, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) Lancet, 397 (2021), pp. 1459-1469 View PDFView articleView in ScopusGoogle Scholar
  • D.R. Feikin, M.M. Higdon, L.J. Abu-Raddad, N. Andrews, R. Araos, Y. Goldberg, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression Lancet, 399 (2022), pp. 924-944 View PDFView articleView in ScopusGoogle Scholar
  • T. Fiolet, Y. Kherabi, C.J. MacDonald, J. Ghosn, N. Peiffer-Smadja Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concerns: a narrative review CMI, 28 (2022), pp. 202-221 View PDFView articleView in ScopusGoogle Scholar
  • P. Almendro-Vázquez, M. Chivite-Lacaba, A. Utrero-Rico, C. González-Cuadrado, R. Laguna-Goya, M. Moreno-Batanero, et al. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses Front Immunol, 13 (2022), p. 981350 View in ScopusGoogle Scholar
  • A. Israel, E. Merzon, A.A. Schaffer, Y. Shenhar, I. Green, A. Golan-Cohen, et al. Elapsed time since Bnt162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study BMJ, 375 (2021), p. e067873 View article CrossRefView in ScopusGoogle Scholar
  • M. Bergwerk, T. Gonen, Y. Lustig, et al. Covid-19 breakthrough infections in vaccinated health care workers N Engl J Med, 385 (2021), pp. 1474-1484 View article CrossRefView in ScopusGoogle Scholar
  • E.G. Levin, Y. Lustig, C. Cohen, R. Fluss, V. Indenbaum, S. Amit, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months N Engl J Med, 385 (2021), p. e84 View article CrossRefView in ScopusGoogle Scholar
  • R.R. Goel, M.M. Painter, K.A. Lundgreen, S.A. Apostolidis, A.E. Baxter, J.R. Giles, et al. Efficient recall of omicron-reactive b cell memory after a third dose of SARS-CoV-2 mRNA vaccine Cell, 185 (2022), pp. 1875-1887 e8 View PDF This article is free to access. View in ScopusGoogle Scholar
  • D. Lozano-Ojalvo, C. Camara, E. Lopez-Granados, P. Nozal, L. Del Pino-Molina, L.Y. Bravo-Gallego, et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and covid-19 recovered individuals Cell Rep, 36 (2021), p. 109570 View PDFView articleView in ScopusGoogle Scholar
  • S. Desmecht, A. Tashkeev, M. El Moussaoui, N. Marechal, H. Perée, Y. Tokunaga, et al. Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and -experienced subjects: impact of booster dose and breakthrough infections Front Immunol, 13 (2022), p. 863554 View in ScopusGoogle Scholar
  • R. Stellini, R. Gianello, W. Gomarasca Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed? Infection, 50 (2022), pp. 1573-1577 View PDF Your institution provides access to this article. CrossRefView in ScopusGoogle Scholar
Fuente de los datos: Dialnet